These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 3057638)

  • 1. Defibrotide: an overview of clinical pharmacology and early clinical studies.
    Cornelli U; Nazzari M
    Semin Thromb Hemost; 1988; 14 Suppl():64-70. PubMed ID: 3057638
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical pharmacology and mode of action of a new antithrombotic compound: Defibrotide.
    Ulutin ON; Cizmeci G; Balkuv-Ulutin S
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):177-80. PubMed ID: 2459016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrinolytic effects of defibrotide in atherosclerotic patients.
    Patrassi GM; Sartori MT; Viero ML; Scapinello MP; Boeri G; Girolami A
    Semin Thromb Hemost; 1991; 17 Suppl 1():101-5. PubMed ID: 2068562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical effectiveness of defibrotide in vaso-occlusive disorders and its mode of actions.
    Ulutin ON
    Semin Thromb Hemost; 1988; 14 Suppl():58-63. PubMed ID: 2848323
    [No Abstract]   [Full Text] [Related]  

  • 5. Defibrotide: properties and clinical use of an old/new drug.
    Pescador R; Capuzzi L; Mantovani M; Fulgenzi A; Ferrero ME
    Vascul Pharmacol; 2013; 59(1-2):1-10. PubMed ID: 23680861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Defibrotide: a new antithrombotic agent].
    Bán A
    Orv Hetil; 2001 Jun; 142(22):1193-4. PubMed ID: 11424595
    [No Abstract]   [Full Text] [Related]  

  • 7. Proceedings of the defibrotide symposium. 8th International Congress on Thrombosis. Istanbul, June 4-7, 1984.
    Haemostasis; 1986; 16 Suppl 1():1-68. PubMed ID: 3754832
    [No Abstract]   [Full Text] [Related]  

  • 8. [Defibrotide].
    Gava R
    G Clin Med; 1988 Mar; 69(3):229-31. PubMed ID: 3169453
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiovascular pharmacology of defibrotide.
    Berti F; Mantovani M; Niada R; Omini C; Pescador R; Porta R; Prinò G; Rossoni G; Tettamanti R
    Semin Thromb Hemost; 1988; 14 Suppl():38-42. PubMed ID: 3057635
    [No Abstract]   [Full Text] [Related]  

  • 10. Deficient fibrinolytic response in patients with Raynaud's phenomenon and its correction with defibrotide.
    Cimminiello C; Milani M; Pietra A; Rossi F; Aloisio M; Nazzari M; Bonfardeci G
    Semin Thromb Hemost; 1991; 17 Suppl 1():106-11. PubMed ID: 2068563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defibrotide: a review on clinical use and future development.
    Larocca A; Cavallo F; Magarotto V; Rossi D; Patriarca F; Boccadoro M; Palumbo A
    Expert Opin Biol Ther; 2008 Aug; 8(8):1201-12. PubMed ID: 18613771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SOS! Defibrotide to the rescue.
    Lazarus HM; McCrae KR
    Blood; 2008 Nov; 112(10):3924-5. PubMed ID: 18988876
    [No Abstract]   [Full Text] [Related]  

  • 13. The pharmacology and clinical pharmacology of defibrotide: a new profibrinolytic, antithrombotic and anti-platelet substance.
    Ulutin ON; Balkuv-Ulutin S; Ugur MS; Ulutin T; Ozsoy Y; Cizmeci G
    Adv Exp Med Biol; 1990; 281():429-38. PubMed ID: 2102624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithrombotic effect and clinical potential of defibrotide.
    Ulutin ON
    Semin Thromb Hemost; 1993; 19 Suppl 1():186-91. PubMed ID: 8362266
    [No Abstract]   [Full Text] [Related]  

  • 15. Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders.
    Palmer KJ; Goa KL
    Drugs; 1993 Feb; 45(2):259-94. PubMed ID: 7681375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absorption through the peritoneum of the macromolecular profibrinolytic drug defibrotide in the rabbit.
    Porta R; Calvani AB; Pescador R; Mantovani M; Prino G
    Semin Thromb Hemost; 1991 Oct; 17(4):404-6. PubMed ID: 1803509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of walking distance by defibrotide in patients with intermittent claudication--results of a randomized, placebo-controlled study (the DICLIS study). Defibrotide Intermittent CLaudication Italian Study.
    Violi F; Marubini E; Coccheri S; Nenci GG
    Thromb Haemost; 2000 May; 83(5):672-7. PubMed ID: 10823260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of the fibrinolytic activity of defibrotide fractions.
    Hizal N; Bilsel S; Emerk K
    Gen Pharmacol; 1994 Dec; 25(8):1617-20. PubMed ID: 7721037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defibrotide protects rabbit myocardium from ischemia: relationship with the eicosanoid system.
    Berti F; Rossini G; Omini C; Daffonchio L; Tondo C; Cali G
    Pol J Pharmacol Pharm; 1987; 39(5):657-65. PubMed ID: 3506734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic profiling of defibrotide in experimental models.
    Fareed J; Walenga JM; Hoppensteadt DA; Kumar A; Ulutin ON; Cornelli U
    Semin Thromb Hemost; 1988; 14 Suppl():27-37. PubMed ID: 2461590
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.